Medpace Holdings, Inc. (NASDAQ:MEDP) Short Interest Down 13.0% in January

Medpace Holdings, Inc. (NASDAQ:MEDP) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totalling 1,000,000 shares, a decline of 13.0% from the December 31st total of 1,150,000 shares. Currently, 3.9% of the shares of the stock are short sold. Based on an average daily volume of 308,700 shares, the short-interest ratio is currently 3.2 days.

Institutional Investors Weigh In On Medpace

Institutional investors have recently bought and sold shares of the stock. Centaurus Financial Inc. lifted its position in Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after purchasing an additional 29 shares during the last quarter. Lindenwold Advisors INC raised its holdings in Medpace by 1.6% during the 3rd quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock valued at $676,000 after buying an additional 32 shares during the last quarter. Stephens Inc. AR boosted its position in Medpace by 4.9% during the 4th quarter. Stephens Inc. AR now owns 752 shares of the company’s stock valued at $250,000 after buying an additional 35 shares during the period. M&T Bank Corp grew its holdings in Medpace by 1.2% in the 3rd quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock worth $1,068,000 after acquiring an additional 37 shares during the last quarter. Finally, Custom Index Systems LLC increased its position in shares of Medpace by 3.0% in the fourth quarter. Custom Index Systems LLC now owns 1,290 shares of the company’s stock valued at $429,000 after acquiring an additional 37 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Price Performance

NASDAQ MEDP traded down $0.89 during trading on Friday, hitting $349.15. 251,703 shares of the company’s stock traded hands, compared to its average volume of 191,848. The stock has a fifty day moving average of $342.28 and a two-hundred day moving average of $353.35. Medpace has a 12-month low of $286.76 and a 12-month high of $459.77. The firm has a market cap of $10.85 billion, a P/E ratio of 30.57, a PEG ratio of 1.76 and a beta of 1.36.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Redburn Atlantic assumed coverage on shares of Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 price objective on the stock. Finally, TD Cowen cut their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.